Treatment of prostate cancer with regional lymph node (N1) metastasis

Alan Pollack, Eric M. Horwitz, Ben Movsas

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Prostate cancer with pathologically documented regional lymph node positive disease has been associated with a dismal prognosis in the past. Clinical and/or biochemical progression is evident within 5 years in over 50% treated with external-beam radiotherapy (EBRT) alone, radical prostatectomy (RP) alone, or androgen deprivation (AD) alone. By 10 years after treatment, greater than 75% progress and over half succumb to prostate cancer. In contrast, the results with the combination of EBRT + AD or RP + AD have been very promising. Ten-year biochemical progression and overall survival rates are roughly 20% and 70%, respectively, for patients with subclinical lymph node involvement. Patients with a 10-year life expectancy should be treated aggressively with long-term AD combined with either EBRT or RP.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalSeminars in Radiation Oncology
Issue number2
StatePublished - Apr 2003
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Treatment of prostate cancer with regional lymph node (N1) metastasis'. Together they form a unique fingerprint.

Cite this